The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study
Study (n=39,151) found 1-year absolute risk of cardiac events was ≈7–10% in patients with lung cancer and malignant melanoma treated with immune checkpoint inhibitors, and risk estimates were higher in this real-world study compared with previous pharmacovigilance studies.
Source:
European Heart Journal
SPS commentary:
An editorial discusses why these figures are higher compared with previous reports and notes these findings highlight that understanding the full nature of potential immune checkpoint inhibitor (ICI)-related cardiac complications and the increased relevance for cardio-oncology care is in its infancy, but given the wide variety for both presentations and the associated morbidity and mortality, treatment approaches represent a challenge. It suggests that perhaps is it time for a broader description of ICI-induced cardiovascular complications to include the term ‘ICI-related cardiovascular disease’ which is supported by the insights of this study.